H.I.G. Capital
H.I.G. Capital, LLC is a private equity and alternative assets investment firm founded in 1993 and headquartered in Miami, Florida, with additional offices in North America, South America, and Europe. The firm specializes in providing both debt and equity capital to small and medium-sized companies, focusing on sectors such as specialty manufacturing, business services, consumer goods, education services, healthcare, and information technology. H.I.G. Capital engages in a variety of investment strategies, including leveraged buyouts, management-led buyouts, corporate carve-outs, and distressed investments. The firm primarily targets companies with enterprise values ranging from $25 million to $1 billion and typically invests between $3 million and $100 million. While it prefers to invest in companies based in the United States, particularly in the Western and Midwest regions, H.I.G. Capital also has a presence in Europe and Latin America. The firm seeks to create value through an operationally focused approach and aims to support the growth of its portfolio companies.
Celerion
Acquisition in 2022
Celerion, Inc. offers a range of clinical research and trial services to pharmaceutical and biotechnology companies, both in the United States and internationally. Founded in 2010 and based in Lincoln, Nebraska, with additional locations in Tempe, Arizona, and West Conshohocken, Pennsylvania, Celerion specializes in Applied Translational Medicine. This approach involves translating research findings into practical insights about drug action and effects in humans, which aids early drug development decisions. The company provides comprehensive services, including global clinical research, data management, biostatistics, medical writing, and bioanalytical services for both small and large molecules. With a clinical capacity of over 600 beds and a network of experienced scientific professionals, Celerion is recognized for its innovative strategies that facilitate early data generation, enabling clients to make informed go/no-go decisions in drug development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.